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Abstract 
Background: Proton MR spectroscopy (MRS) is able to detect and quantify different 
metabolites in the central nervous system, and has been widely studied in multiple 
sclerosis (MS). These include: N-acetyl aspartate (NAA) and N-
acetylaspartylglutamate (NAAG) (both markers of neuronal integrity); myoinositol 
(mI, a marker of glial proliferation); glutamate and glutamine (Glx, representing a 
mixture of aminoacids acting as excitatory and inhibitory neurotransmitters); creatine 
and phosphocreatinine (Cr+PCr, suggested marker of gliosis); and 
glycerophosphocholine+phosphocholine (GPC+PCh, markers of membrane 
phospholipids, highly suggestive of ongoing inflammation when elevated). 
Normalization of metabolite levels to Cr+PCr has several advantages, including the 
reduced influence of inhomogeneities and relaxation parameters. 
 
Aim: To examine metabolite concentrations using MRS, in 120 secondary 
progressive MS (SPMS) patients, and to correlate them with clinical and 
demographic measures. 
 
Method: 120 SPMS patients, enrolled in the MS-SMART trial (NCT01910259) were 
studied at baseline by 1H-MRS. The mean values of GPC+PCh/Cr+PCr; 
NAA+NAAG/Cr+PCr; Glx /Cr+PCr; mI/Cr were calculating by considering one single 
voxel of normal appearing white matter (NAWM) in each hemisphere. Kendall's tau-b 
coefficients were used to test the correlations between the variables. Two sample t-
tests were performed to test for differences between gender groups and EDSS band. 
 
Results: There were no significant associations between any of the metabolites 
studied and: age, EDSS, total disease duration, SPMS duration and time since 
diagnosis. NAA+NAAG/Cr+PCr was significantly higher in females (p = 0.02) and 
mI/Cr was significantly higher in males (p < 0.01). 
 
Conclusion: Our initial cross-sectional results show that the metabolic processes 
underlying the progression of the disease may differ between males and females, 
and ultimately could affect clinical course. 
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